Health
J&J’s COVID-19 vaccine 66 per cent effective in trial – The Tribune India
The vaccine is 85 per cent effective in stopping severe disease and preventing hospitalisation
January 29
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large trial against multiple variants across three continents.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.
A high bar has been set by two authorised vaccines from Pfizer/BioNTech and Moderna,…
-
Noosa News22 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
Noosa News22 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News24 hours agoHelicopter scrambles to site of air crash on K’gari
-
General21 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off